Zydus Lifesciences Ltd
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20.
Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe
- Market Cap ₹ 36,624 Cr.
- Current Price ₹ 358
- High / Low ₹ 655 / 319
- Stock P/E 8.33
- Book Value ₹ 166
- Dividend Yield 0.70 %
- ROCE 26.3 %
- ROE 29.3 %
- Face Value ₹ 1.00
Pros
- Company has delivered good profit growth of 24.19% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 17.65%
Cons
- The company has delivered a poor sales growth of 10.24% over past five years.
- Tax rate seems low
- Earnings include an other income of Rs.2583.10 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
4,631 | 5,263 | 6,358 | 7,224 | 8,651 | 9,427 | 9,376 | 11,905 | 13,166 | 14,253 | 15,102 | 15,265 | |
3,602 | 4,177 | 5,228 | 6,021 | 6,896 | 7,095 | 7,474 | 9,074 | 10,174 | 11,455 | 11,758 | 11,924 | |
Operating Profit | 1,028 | 1,086 | 1,130 | 1,203 | 1,756 | 2,332 | 1,902 | 2,831 | 2,991 | 2,798 | 3,344 | 3,341 |
OPM % | 22% | 21% | 18% | 17% | 20% | 25% | 20% | 24% | 23% | 20% | 22% | 22% |
11 | 49 | 32 | 30 | 45 | 112 | 127 | 111 | 183 | -264 | -171 | 2,583 | |
Interest | 70 | 183 | 169 | 90 | 68 | 53 | 45 | 91 | 194 | 342 | 164 | 127 |
Depreciation | 127 | 158 | 185 | 201 | 287 | 292 | 373 | 539 | 599 | 696 | 725 | 713 |
Profit before tax | 842 | 794 | 809 | 942 | 1,446 | 2,099 | 1,612 | 2,312 | 2,382 | 1,495 | 2,285 | 5,084 |
Tax % | 13% | 14% | 15% | 11% | 18% | 8% | 8% | 24% | 22% | 21% | 6% | 10% |
Net Profit | 711 | 653 | 654 | 804 | 1,151 | 1,934 | 1,488 | 1,776 | 1,849 | 1,177 | 2,134 | 4,487 |
EPS in Rs | 6.95 | 6.37 | 6.38 | 7.85 | 11.24 | 18.89 | 14.53 | 17.35 | 18.06 | 11.49 | 20.84 | 43.83 |
Dividend Payout % | 18% | 24% | 24% | 23% | 21% | 17% | 22% | 20% | 19% | 30% | 17% | 6% |
Compounded Sales Growth | |
---|---|
10 Years: | 11% |
5 Years: | 10% |
3 Years: | 5% |
TTM: | 1% |
Compounded Profit Growth | |
---|---|
10 Years: | 21% |
5 Years: | 24% |
3 Years: | 35% |
TTM: | 92% |
Stock Price CAGR | |
---|---|
10 Years: | 9% |
5 Years: | -7% |
3 Years: | 14% |
1 Year: | -44% |
Return on Equity | |
---|---|
10 Years: | 23% |
5 Years: | 21% |
3 Years: | 22% |
Last Year: | 29% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | |
Reserves | 2,069 | 2,484 | 2,842 | 3,337 | 4,149 | 5,597 | 6,858 | 8,642 | 10,284 | 10,273 | 12,890 | 16,897 |
1,092 | 2,289 | 2,918 | 2,700 | 2,651 | 2,442 | 5,207 | 5,407 | 7,899 | 7,986 | 4,584 | 4,221 | |
1,348 | 1,548 | 1,512 | 1,847 | 2,144 | 2,208 | 2,937 | 3,632 | 4,945 | 5,115 | 6,189 | 6,575 | |
Total Liabilities | 4,611 | 6,423 | 7,374 | 7,986 | 9,047 | 10,350 | 15,104 | 17,783 | 23,231 | 23,477 | 23,765 | 27,795 |
1,833 | 2,857 | 3,026 | 3,124 | 3,352 | 3,748 | 5,755 | 6,483 | 12,164 | 12,230 | 12,133 | 12,253 | |
CWIP | 431 | 484 | 736 | 892 | 798 | 951 | 1,543 | 1,527 | 837 | 742 | 783 | 661 |
Investments | 21 | 24 | 114 | 87 | 154 | 416 | 435 | 746 | 674 | 765 | 830 | 3,288 |
2,326 | 3,058 | 3,498 | 3,885 | 4,743 | 5,235 | 7,371 | 9,028 | 9,556 | 9,740 | 10,019 | 11,593 | |
Total Assets | 4,611 | 6,423 | 7,374 | 7,986 | 9,047 | 10,350 | 15,104 | 17,783 | 23,231 | 23,477 | 23,765 | 27,795 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
683 | 511 | 603 | 903 | 994 | 1,894 | 1,312 | 919 | 1,282 | 2,932 | 3,293 | 2,104 | |
-466 | -1,200 | -682 | -438 | -465 | -860 | -2,872 | -974 | -3,977 | -1,004 | -835 | 1,154 | |
-172 | 860 | 286 | -529 | -351 | -935 | 2,316 | 52 | 1,885 | -1,528 | -2,549 | -868 | |
Net Cash Flow | 44 | 171 | 207 | -64 | 178 | 99 | 756 | -3 | -811 | 399 | -90 | 2,390 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 60 | 64 | 55 | 57 | 67 | 68 | 89 | 98 | 110 | 94 | 76 | 80 |
Inventory Days | 201 | 234 | 191 | 184 | 175 | 158 | 193 | 211 | 208 | 207 | 227 | 245 |
Days Payable | 141 | 117 | 103 | 123 | 125 | 154 | 165 | 167 | 149 | 152 | 155 | 141 |
Cash Conversion Cycle | 120 | 181 | 142 | 119 | 118 | 71 | 116 | 142 | 169 | 149 | 148 | 184 |
Working Capital Days | 53 | 58 | 63 | 46 | 56 | 46 | 62 | 95 | 99 | 79 | 69 | 171 |
ROCE % | 31% | 24% | 18% | 18% | 23% | 29% | 16% | 18% | 15% | 12% | 15% | 26% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1d - Newspaper advertisement published in the Financial Express English and Gujarati Edition with regard to Special Window Facility for Senior Citizens of age 75 years & …
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
23 Jun - Newspaper Publication of Notice of loss of share certificate of the Company, published in the Financial Express English and Gujarati Editions, both on June 23, …
- Buyback Offer Opening Advertisement Published In Newspapers 20 Jun
- Appointment Of Mr. Pankaj R. Patel As A Part Time Non-Official Director In The Central Board Of The Reserve Bank Of Lndia (Rbl) 14 Jun
- Letter Of Offer 13 Jun
Annual reports
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
Concalls
-
Transcript - May 22
-
Transcript - Feb 22
-
Transcript - Nov 21
-
Transcript - Sep 21
-
Transcript - Aug 21
-
Transcript - May 21
-
Transcript - Feb 21
-
Transcript - Oct 20
-
Transcript - Jul 20
-
Transcript - Jun 20
-
Transcript - Mar 20
-
Transcript - Nov 19
-
Transcript - Jul 19
-
Transcript - May 19
-
Transcript - May 18
-
Transcript - May 17
-
Transcript - Jan 17
-
Transcript - Oct 16
-
Transcript - May 16
US Generic business (45% of revenues)
Ranked 4th among US generic companies [1], having grown sales from ~$211 mn in FY11 to $828mn in FY20
Has secured highest number of ANDA approvals (#230) in last 4 years, [2] with total 337 ANDA approvals, 117 DMF filings and 190+ launched products [2]
Has a rich pipeline of complex generics including injectables, orphan and specialty drugs addressing market size of ~$119bn [3]
Plans to file ~40 ANDA and 1 NDA per year over the next 3 years. [4]
Spends 7-8% of revenues in R&D [5]